Melanoma drug wins US approval

Nature. 2011 Mar 31;471(7340):561. doi: 10.1038/471561a.
No abstract available

Publication types

  • News

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use*
  • Antigens, CD / immunology
  • Antineoplastic Agents / immunology
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols
  • CTLA-4 Antigen
  • Clinical Trials as Topic
  • Drug Approval*
  • Humans
  • Immunotherapy / methods
  • Ipilimumab
  • Melanoma / drug therapy*
  • Melanoma / genetics
  • Melanoma / immunology
  • Melanoma / pathology
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors
  • Proto-Oncogene Proteins B-raf / genetics
  • Survival Analysis
  • United States
  • United States Food and Drug Administration

Substances

  • Antibodies, Monoclonal
  • Antigens, CD
  • Antineoplastic Agents
  • CTLA-4 Antigen
  • CTLA4 protein, human
  • Ipilimumab
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf